120 related articles for article (PubMed ID: 35370291)
1. Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas.
Wang Z; Zhu L; Li K; Sun Y; Giamas G; Stebbing J; Peng L; Yu Z
Cancer Gene Ther; 2022 Oct; 29(10):1418-1428. PubMed ID: 35370291
[TBL] [Abstract][Full Text] [Related]
2. Clear cell renal cell carcinoma: immunological significance of alternative splicing signatures.
Zhang J; Jiang H; Rao D; Jin X
Front Oncol; 2023; 13():1206882. PubMed ID: 38288096
[TBL] [Abstract][Full Text] [Related]
3. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
Front Oncol; 2021; 11():778637. PubMed ID: 35004299
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
Zhang D; Zhang W; Sun R; Huang Z
Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
[TBL] [Abstract][Full Text] [Related]
5. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
[TBL] [Abstract][Full Text] [Related]
6. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
7. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
9. Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
Liu J; Deng W; Xiao Z; Huang X; Lin M; Long Z
J Immunol Res; 2022; 2022():8976179. PubMed ID: 36157883
[TBL] [Abstract][Full Text] [Related]
10. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma.
Zhang Z; Tang Y; Liu Y; Zhuang H; Lin E; Xie L; Feng X; Tian K; Zeng J; Liu J; Yu Y
J Immunol Res; 2021; 2021():9921466. PubMed ID: 34368371
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis.
Zhou L; Ye J; Wen F; Yu H
Dis Markers; 2022; 2022():4033583. PubMed ID: 35320950
[TBL] [Abstract][Full Text] [Related]
13. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
14. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
[TBL] [Abstract][Full Text] [Related]
15. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
16. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Immune Infiltration Signatures of GIMAP Family Genes in Clear Cell Renal Cell Carcinoma.
Zhang M; Zhang X; Hou J; Liang X; Zhang M
Front Biosci (Landmark Ed); 2023 Nov; 28(11):308. PubMed ID: 38062816
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma.
Fu L; Bao J; Li J; Li Q; Lin H; Zhou Y; Li J; Yan Y; Langston ME; Sun T; Guo S; Zhou X; Chen Y; Liu Y; Zhao Y; Lu J; Huang Y; Chen W; Chung BI; Luo J
Front Immunol; 2022; 13():1021935. PubMed ID: 36248876
[TBL] [Abstract][Full Text] [Related]
20. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
[Next] [New Search]
